Description
Anti-Nono Antibody, Non-Fucosylated (BioBet-1473ZP) is a human monoclonal IgG antibody against Nono. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Colon Cancer; Lung Cancer; Breast Cancer; Ovary Cancer; Pancreatic Cancers; Lympoma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Nono antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
non-POU domain-containing octamer-binding protein
Background
PAT-LM1 is a natural human antibody that has shown great promise in laboratory and animal testing as a potential treatment for multiple types of cancer, with a particularly strong potency against colon, lung, breast, ovary and pancreatic cancers.
Alternative Names
NONO ; NMT55; NRB54; P54; P54NRB; PPP1R114
Cellular Localization
Nucleus
Involvement in Disease
Diseases associated with NONO include Mental Retardation, X-Linked, Syndromic 34 and Renal Cell Carcinoma, Xp11-Associated.
Related Pathways
Its related pathways are Development NOTCH1-mediated pathway for NF-KB activity modulation and Circadian rythm related genes.
Function
DNA and RNA binding proteins are involved in several nuclear processes. Incorporate traditional octamer sequences in double-stranded DNA. It also binds single-stranded DNA and RNA at a separate double site. Participate in pre-mRNA splicing, possibly as a heterodimer with SFPQ. Interaction with U5 snRNA may be by binding to the purine-rich sequence located on the 3'side of U5 snRNA stem 1b. Together with PSPC1, it is necessary to form paranuclear lines. The SFPQ-NONO isomer related to Sophora flavescens 3 may play a role in the nuclear retention of defective RNA. The SFPQ-NONO isomer may participate in DNA melting by regulating the function of topoisomerase I/TOP1. SFPQ-NONO isoforms may be involved in double-strand break repair and DNA non-homologous end joining (NHEJ) required for V(D)J recombination, and may stabilize paired DNA ends. In vitro, the complex strongly stimulates the DNA end connection, directly binds to the DNA substrate, and cooperates with the Ku70/G22P1-Ku80/XRCC5 (Ku) dimer to establish a functional pre-connection complex. NONO is involved in transcriptional regulation. The SFPQ-NONO-NR5A1 complex binds to the CYP17 promoter to regulate basic and camp-dependent transcriptional activity. NONO binds to enhancer elements in the long terminal repeats of endogenous A particles (IAPs) and activates transcription. Regulate the biological clock by inhibiting the transcriptional activator activity of the clock-arntl/BMAL1 heterodimer. It is important for the functional organization of gaba synapses. Through the regulation of GABRA2 transcript, it plays a special and important role in the regulation of synaptic RNA and GPHN/gephyrin scaffold structure. By assembling into HDP-RNP complex, it regulates the innate immune response mediated by DNA virus. The complex provides a platform for phosphorylation of IRF3 and activation of the innate immune response through the cGAS-STING pathway.
Post-translational modifications
The N-terminus is blocked.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-1473ZP
Description
PAT-LM1 bingding to non-POU domain-containing octamer-binding protein (NONO) is a natural human antibody that can be used as a potential treatment for multiple types of cancer, with a particularly strong potency against colon, lung, breast, ovary, pancreatic cancers, lympoma.
Antibody Indication
Colon Cancer; Lung Cancer; Breast Cancer; Ovary Cancer; Pancreatic Cancers; Lympoma
